181 related articles for article (PubMed ID: 19177354)
21. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
22. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain.
Craig A; Scott M; Burch L; Smith G; Ball K; Hupp T
EMBO Rep; 2003 Aug; 4(8):787-92. PubMed ID: 12897801
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
24. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.
Chaturvedi P; Eng WK; Zhu Y; Mattern MR; Mishra R; Hurle MR; Zhang X; Annan RS; Lu Q; Faucette LF; Scott GF; Li X; Carr SA; Johnson RK; Winkler JD; Zhou BB
Oncogene; 1999 Jul; 18(28):4047-54. PubMed ID: 10435585
[TBL] [Abstract][Full Text] [Related]
25. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.
Cai Z; Chehab NH; Pavletich NP
Mol Cell; 2009 Sep; 35(6):818-29. PubMed ID: 19782031
[TBL] [Abstract][Full Text] [Related]
26. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
[TBL] [Abstract][Full Text] [Related]
27. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
[TBL] [Abstract][Full Text] [Related]
28. Benzimidazole inhibitors of the protein kinase CHK2: clarification of the binding mode by flexible side chain docking and protein-ligand crystallography.
Matijssen C; Silva-Santisteban MC; Westwood IM; Siddique S; Choi V; Sheldrake P; van Montfort RL; Blagg J
Bioorg Med Chem; 2012 Nov; 20(22):6630-9. PubMed ID: 23058106
[TBL] [Abstract][Full Text] [Related]
29. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
30. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
Jin J; Ang XL; Ye X; Livingstone M; Harper JW
J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
[TBL] [Abstract][Full Text] [Related]
31. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68.
Wei JH; Chou YF; Ou YH; Yeh YH; Tyan SW; Sun TP; Shen CY; Shieh SY
J Biol Chem; 2005 Mar; 280(9):7748-57. PubMed ID: 15618221
[TBL] [Abstract][Full Text] [Related]
32. Identification of the hot spot residues for pyridine derivative inhibitor CCT251455 and ATP substrate binding on monopolar spindle 1 (MPS1) kinase by molecular dynamic simulation.
Chen K; Duan W; Han Q; Sun X; Li W; Hu S; Wan J; Wu J; Ge Y; Liu D
J Biomol Struct Dyn; 2019 Feb; 37(3):611-622. PubMed ID: 29380674
[TBL] [Abstract][Full Text] [Related]
33. ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Wang J; Wiltshire T; Wang Y; Mikell C; Burks J; Cunningham C; Van Laar ES; Waters SJ; Reed E; Wang W
J Biol Chem; 2004 Sep; 279(38):39584-92. PubMed ID: 15269203
[TBL] [Abstract][Full Text] [Related]
34. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456.
Kass EM; Ahn J; Tanaka T; Freed-Pastor WA; Keezer S; Prives C
J Biol Chem; 2007 Oct; 282(41):30311-21. PubMed ID: 17715138
[TBL] [Abstract][Full Text] [Related]
35. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel, selective and potent Chk2 inhibitors.
Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
[TBL] [Abstract][Full Text] [Related]
37. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine.
Sharma V; Tepe JJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4319-21. PubMed ID: 15261294
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.
Jiang X; Zhao B; Britton R; Lim LY; Leong D; Sanghera JS; Zhou BB; Piers E; Andersen RJ; Roberge M
Mol Cancer Ther; 2004 Oct; 3(10):1221-7. PubMed ID: 15486189
[TBL] [Abstract][Full Text] [Related]
39. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.
Urist M; Tanaka T; Poyurovsky MV; Prives C
Genes Dev; 2004 Dec; 18(24):3041-54. PubMed ID: 15601819
[TBL] [Abstract][Full Text] [Related]
40. M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.
Evison BJ; Pastuovic M; Bilardi RA; Forrest RA; Pumuye PP; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Biochem Pharmacol; 2011 Dec; 82(11):1604-18. PubMed ID: 21889927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
